Marija Plodinec studied physics in Zagreb and received her doctorate in 2010 from the Maurice Müller Institute at the Biozentrum of the University of Basel. Dr. Plodinec is a recognized expert in the field of physical sciences in oncology and has co-authored important scientific papers and patents in this field. She is also a member of several international organizations focusing on cancer research and its clinical applications. She is a Senior Principal Scientist at the University Hospital Basel since may 2015.
She co-founded ARTIDIS™ AG to further develop and market this platform for cancer diagnosis and prognosis. Since November 2017 she serves as the CEO of ARTIDIS™ AG and as a Member of its Board of Directors.
She has been instrumental in the development of ARTIDIS™, a device capable of distinguishing benign from malignant tissue. During her many years as a research associate at the Biozentrum of the University of Basel and as a project leader at the University Hospital Basel, she has brought this technology from basic research to the first clinical studies.
ARTIDIS™, is an innovative nanotechnology tool for cancer diagnosis and treatment, seeks to improve people’s lives by dramatically reducing the time it takes to accurately diagnose breast cancer – from a period of days or weeks to as little as three hours —thereby substantially reducing anxiety and time lost.